Pharvaris to Present Clinical Data at the ACAAI 2025 Annual Scientific Meeting

Rhea-AI Summary

Pharvaris (Nasdaq: PHVS) announced acceptance of 2 oral and 6 poster presentations at the American College of Allergy, Asthma, and Immunology (ACAAI) 2025 Annual Scientific Meeting in Orlando, November 6–10, 2025.

Presentations focus on clinical data for oral deucrictibant in hereditary angioedema (prophylaxis and on‑demand treatment), biomarker assay validation, long‑term safety and efficacy (CHAPTER‑1 and RAPIDe‑2), and pharmacokinetics of an extended‑release tablet. Slides and posters will be posted on the company's investor website at presentation start times.

ZUG, Switzerland, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of two abstracts for oral presentation and six for poster presentation at the American College of Allergy, Asthma, and Immunology (ACAAI) 2025 Annual Scientific Meeting to be held from November 6-10, in Orlando, Florida.

Details of the presentations are as follows:

ACAAI 2025, Orlando, Florida, November 6-10, 2025.
Oral Presentations

• Title: Clinical Validation of a Kinin Biomarker Assay to Characterize Bradykinin-Mediated Angioedema
  Presenter: Evangelia Pardali, Ph.D.
  Format: Oral Presentation
  Date, time: Saturday, November 8, 4:43 p.m. ET

• Title: Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: CHAPTER-1 Open-Label Extension
  Presenter: Marc A. Riedl, M.D., M.S.
  Format: Oral Presentation
  Date, time: Saturday, November 8, 4:53 p.m. ET
  
  

Poster Presentations

• Title: Long-Term Prophylactic Treatment with Oral Deucrictibant Improved Disease Control and Health-Related Quality of Life in Hereditary Angioedema: CHAPTER-1
  Presenter: Michael E. Manning, M.D.
  Format: Poster Presentation
  Date, time: Friday, November 7, 2:35 p.m. ET

• Title: Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: RAPIDe-2 Results
  Presenter: John Anderson, M.D.
  Format: Poster Presentation
  Date, time: Friday, November 7, 2:35 p.m. ET

• Title: Deucrictibant vs. Standard of Care in Hereditary Angioedema: A Propensity Score-Matched Analysis
  Presenter: Mark D. Scarupa, M.D.
  Format: Poster Presentation
  Date, time: Friday, November 7, 4:35 p.m. ET

• Title: Durability of Response to Single Dose Oral Deucrictibant for On-Demand Treatment of Hereditary Angioedema Attacks
  Presenter: Joshua S. Jacobs, M.D.
  Format: Poster Presentation
  Date, time: Friday, November 7, 5:05 p.m. ET

• Title: Outcomes of Deucrictibant-Treated Upper Airway and Laryngeal Hereditary Angioedema Attacks: RAPIDe-2 Part A Results
  Presenter: John Anderson, M.D.
  Format: Poster Presentation
  Date, time: Friday, November 7, 5:20 p.m. ET

• Title: Sustained Therapeutic Exposure with Once-Daily Oral Deucrictibant Extended-Release Tablet for Prophylaxis of Hereditary Angioedema Attacks
  Presenter: Zhi-Yi Zhang, Ph.D.
  Format: Poster Presentation
  Date, time: Friday, November 7, 5:35 p.m. ET
  
  

The posters and presentation slides will be made available on the Investors section of the Pharvaris website at the beginning of the respective presentations at: https://ir.pharvaris.com/news-events/events-presentations.

About Pharvaris
Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to potentially address all types of bradykinin-mediated angioedema. Pharvaris intends to provide injectable-like efficacy™ and placebo-like tolerability with the convenience of oral therapies to prevent and treat bradykinin-mediated angioedema attacks. With positive data in both Phase 2 prophylaxis and on-demand studies in HAE, Pharvaris is currently evaluating the efficacy and safety of deucrictibant in a pivotal Phase 3 study for the prevention of HAE attacks (CHAPTER-3) and a pivotal Phase 3 study for the on-demand treatment of HAE attacks (RAPIDe-3). For more information, visit https://pharvaris.com/.

Contact
Maggie Beller
Executive Director, Head of Corporate and Investor Communications
maggie.beller@pharvaris.com

FAQ

When will Pharvaris (PHVS) present at ACAAI 2025 in Orlando?

Pharvaris has presentations scheduled during ACAAI 2025, held November 6–10, 2025; oral presentations occur on November 8, 2025.

How many Pharvaris abstracts were accepted for ACAAI 2025 and what types?

Pharvaris has 2 oral abstracts and 6 poster abstracts accepted for ACAAI 2025.

Which Pharvaris clinical programs are featured in the ACAAI 2025 presentations (PHVS)?

Presentations feature clinical data for oral deucrictibant, including CHAPTER‑1 open‑label extension and RAPIDe‑2 results, plus a kinin biomarker assay and an extended‑release tablet profile.

Where can investors find Pharvaris (PHVS) ACAAI 2025 slides and posters?

Slides and posters will be posted at the start of each presentation on Pharvaris' investor website: https://ir.pharvaris.com/news-events/events-presentations.

What topics will Pharvaris oral presentations cover at ACAAI 2025?

Oral talks cover clinical validation of a kinin biomarker assay and long‑term safety and efficacy of oral deucrictibant for HAE prophylaxis (CHAPTER‑1 OLE).